61.35
price down icon5.10%   -3.30
after-market After Hours: 60.46 -0.89 -1.45%
loading
Verona Pharma Plc Adr stock is traded at $61.35, with a volume of 1.63M. It is down -5.10% in the last 24 hours and up +4.43% over the past month. Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
See More
Previous Close:
$64.65
Open:
$64
24h Volume:
1.63M
Relative Volume:
1.27
Market Cap:
$5.21B
Revenue:
-
Net Income/Loss:
$-153.72M
P/E Ratio:
-30.68
EPS:
-2
Net Cash Flow:
$-103.81M
1W Performance:
-7.00%
1M Performance:
+4.43%
6M Performance:
+118.79%
1Y Performance:
+278.00%
1-Day Range:
Value
$59.50
$64.59
1-Week Range:
Value
$59.50
$69.90
52-Week Range:
Value
$11.39
$70.40

Verona Pharma Plc Adr Stock (VRNA) Company Profile

Name
Name
Verona Pharma Plc Adr
Name
Phone
011-44-0-2032834200
Name
Address
3 MORE LONDON RIVERSIDE, LONDON
Name
Employee
209
Name
Twitter
@VeronaPharma
Name
Next Earnings Date
2024-11-04
Name
Latest SEC Filings
Name
VRNA's Discussions on Twitter

Compare VRNA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
VRNA
Verona Pharma Plc Adr
61.35 5.21B 0 -153.72M -103.81M -2.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
500.01 128.40B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
744.83 81.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
571.00 34.69B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
233.07 30.17B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beone Medicines Ltd Adr
242.66 26.02B 3.32B -860.46M -1.04B -8.32

Verona Pharma Plc Adr Stock (VRNA) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-10-25 Initiated ROTH MKM Buy
Oct-03-24 Initiated Wells Fargo Overweight
May-22-23 Resumed Jefferies Buy
Sep-19-22 Resumed Wedbush Outperform
Aug-26-22 Initiated Piper Sandler Overweight
Sep-13-21 Initiated H.C. Wainwright Buy
Aug-25-20 Initiated Jefferies Buy
Aug-10-20 Initiated Canaccord Genuity Buy
Apr-18-19 Initiated BTIG Research Buy
View All

Verona Pharma Plc Adr Stock (VRNA) Latest News

pulisher
Mar 10, 2025

Keeping an Eye on Gilead Sciences, Inc (GILD) After Insider Trading Activity - Knox Daily

Mar 10, 2025
pulisher
Mar 10, 2025

McEwen Mining Inc (MUX) Becoming More Attractive for Investors - Knox Daily

Mar 10, 2025
pulisher
Mar 10, 2025

Morgan Stanley Upgrades Solaredge Technologies Inc (SEDG) to an Equal-weight from an Underweight - Knox Daily

Mar 10, 2025
pulisher
Mar 10, 2025

Verona Pharma at Leerink Global Healthcare: Eutuvera’s Promising Launch By Investing.com - Investing.com UK

Mar 10, 2025
pulisher
Feb 28, 2025

Earnings call transcript: Verona Pharma Q4 2024 beats EPS & revenue forecasts By Investing.com - Investing.com South Africa

Feb 28, 2025
pulisher
Feb 27, 2025

Verona Pharma stock surges as Q4 revenue soars past estimates - Investing.com India

Feb 27, 2025
pulisher
Feb 27, 2025

Verona Pharma stock surges as Q4 revenue soars past estimates By Investing.com - Investing.com Canada

Feb 27, 2025
pulisher
Feb 27, 2025

Earnings call transcript: Verona Pharma Q4 2024 beats EPS & revenue forecasts - Investing.com

Feb 27, 2025
pulisher
Feb 27, 2025

Verona Pharma plc (NASDAQ:VRNA) Q4 2024 Earnings Call Transcript - MSN

Feb 27, 2025
pulisher
Feb 27, 2025

Verona Pharma ADR earnings beat by $0.02, revenue topped estimates - Investing.com UK

Feb 27, 2025
pulisher
Feb 21, 2025

A company insider recently sold 640,264 shares of Verona Pharma Plc ADR [VRNA]. Should You Sale? - Knox Daily

Feb 21, 2025
pulisher
Feb 13, 2025

Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update - GlobeNewswire Inc.

Feb 13, 2025
pulisher
Feb 12, 2025

Verona Pharma stock soars to all-time high of $62.09 - Investing.com India

Feb 12, 2025
pulisher
Feb 12, 2025

Verona Pharma stock soars to all-time high of $62.09 By Investing.com - Investing.com South Africa

Feb 12, 2025
pulisher
Feb 12, 2025

Canaccord raises Verona Pharma target to $72; maintains buy By Investing.com - Investing.com South Africa

Feb 12, 2025
pulisher
Feb 11, 2025

Investor’s Delight: Lithium Americas Corp (NewCo) (LAC) Closes Weak at 2.97, Down -1.98 - The Dwinnex

Feb 11, 2025
pulisher
Feb 11, 2025

There is no doubt that Verona Pharma Plc ADR (VRNA) ticks all the boxes. - SETE News

Feb 11, 2025
pulisher
Feb 11, 2025

Analyzing Verona Pharma Plc ADR (VRNA) After Recent Trading Activity - Knox Daily

Feb 11, 2025
pulisher
Feb 11, 2025

Rumble Inc (RUM)’s Market Momentum: Closing Strong at 12.25, Down -3.92 - The Dwinnex

Feb 11, 2025
pulisher
Feb 11, 2025

Market Recap Check: Lineage Cell Therapeutics Inc (LCTX)’s Negative Finish at 0.66, Up/Down -2.12 - The Dwinnex

Feb 11, 2025
pulisher
Feb 11, 2025

A History of Outperforming Analyst Forecasts and Beating the Odds: OrganiGram Holdings Inc (OGI) - SETE News

Feb 11, 2025
pulisher
Feb 06, 2025

Are Smart Investors Making the Right Decision? Verona Pharma Plc ADR (VRNA) - SETE News

Feb 06, 2025
pulisher
Feb 06, 2025

Healthy Upside Potential: Solidion Technology Inc (STI) - SETE News

Feb 06, 2025
pulisher
Feb 05, 2025

Stock Surge: XPO Inc (XPO) Closes at 131.50, Marking a 2.24 Increase/Decrease - The Dwinnex

Feb 05, 2025
pulisher
Feb 05, 2025

Closing Figures Unveiled: Diageo plc ADR (DEO) Drop -0.84, Closes at 115.95 - The Dwinnex

Feb 05, 2025
pulisher
Feb 05, 2025

Market Watch Highlights: Verona Pharma Plc ADR (VRNA) Ends on an Upturn Note at 59.94 - The Dwinnex

Feb 05, 2025
pulisher
Feb 05, 2025

Market Momentum Report: Lemonade Inc (LMND)’s Positive Close at 33.99 - The Dwinnex

Feb 05, 2025
pulisher
Feb 05, 2025

Stock Market News and Commentary - Barchart

Feb 05, 2025
pulisher
Feb 04, 2025

Verona Pharma Keeps Hitting New Highs - Barchart

Feb 04, 2025
pulisher
Feb 04, 2025

An Analysis of Knowles Corp (KN)’s Potential Price Growth - Knox Daily

Feb 04, 2025
pulisher
Feb 04, 2025

Checking in on Verona Pharma Plc ADR (VRNA) after recent insiders movement - Knox Daily

Feb 04, 2025
pulisher
Feb 04, 2025

A closer look at Centessa Pharmaceuticals plc ADR (CNTA) is warranted - US Post News

Feb 04, 2025
pulisher
Feb 04, 2025

Have you been able to find a good deal on Verona Pharma Plc ADR’s shares? - US Post News

Feb 04, 2025
pulisher
Feb 04, 2025

The Agilon Health Inc (AGL) had a good session last reading, didn’t it? - US Post News

Feb 04, 2025
pulisher
Feb 04, 2025

How should investors view Relay Therapeutics Inc (RLAY)? - US Post News

Feb 04, 2025
pulisher
Jan 21, 2025

Verona Pharma stock target upgraded, retains buy on Q4 results By Investing.com - Investing.com South Africa

Jan 21, 2025
pulisher
Jan 17, 2025

Looking For A Top Momentum Pick? Why Valley National Bancorp (NASDAQ: VLY) Is A Great Choice - Stocks Register

Jan 17, 2025
pulisher
Jan 17, 2025

Hertz Global Holdings Inc (NASDAQ: HTZ): Overvalued Compared To Others? - Stocks Register

Jan 17, 2025
pulisher
Jan 17, 2025

Verona Pharma Plc ADR (VRNA) Outlook: Looking Back For Insights - Stocks Register

Jan 17, 2025
pulisher
Jan 16, 2025

Why Verona Pharma, A Triple-Digit Gainer In 2024, Surged Another 19% This Week - Yahoo! Voices

Jan 16, 2025
pulisher
Jan 08, 2025

Verona Pharma stock target increased, keeps buy on Q4 sales By Investing.com - Investing.com South Africa

Jan 08, 2025
pulisher
Jan 07, 2025

Verona Pharma stock soars to all-time high of $49.05 - Investing.com India

Jan 07, 2025
pulisher
Jan 03, 2025

Here are some of BTIG's top picks for the first half of 2025 - Investing.com

Jan 03, 2025
pulisher
Dec 29, 2024

European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading - MSN

Dec 29, 2024
pulisher
Dec 23, 2024

Verona Pharma stock soars to all-time high of $43.76 - Investing.com

Dec 23, 2024
pulisher
Dec 10, 2024

Ligand forecasts revenue growth and higher earnings for 2025 - Investing.com

Dec 10, 2024
pulisher
Dec 07, 2024

Verona Pharma CFO Mark Hahn sells shares worth $4.4 million - Investing.com India

Dec 07, 2024
pulisher
Dec 06, 2024

Verona Pharma CEO David Zaccardelli sells shares worth $4.36 million - Investing.com

Dec 06, 2024
pulisher
Dec 02, 2024

Verona Pharma's CFO Mark Hahn sells shares worth $566,821 - Investing.com India

Dec 02, 2024
pulisher
Dec 02, 2024

Verona Pharma's CFO Mark Hahn sells shares worth $566,821 By Investing.com - Investing.com South Africa

Dec 02, 2024
pulisher
Dec 02, 2024

Verona Pharma CEO David Zaccardelli sells shares worth $627,233 - Investing.com

Dec 02, 2024

Verona Pharma Plc Adr Stock (VRNA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$35.96
price up icon 0.98%
$21.98
price down icon 8.97%
$32.75
price down icon 0.79%
$317.87
price up icon 0.62%
$105.35
price down icon 3.15%
biotechnology ONC
$242.66
price down icon 1.78%
Cap:     |  Volume (24h):